Details of the Drug

General Information of Drug (ID: DMNSC0O)

Drug Name

DNL747

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]
Amyotrophic lateral sclerosis	8B60.0	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Receptor-interacting protein 1 (RIPK1)	TTAIQSN	RIPK1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03757325) Study to Evaluate DNL747 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT03757351) Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health.
3	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.